News | April 24, 2026
Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Subscribe To Our Newsletter & Stay Updated
